Table 3.
Frequency of Peptide-specific CTLp Directed to Flu Matrix58–66 in the Context of HLA-A*0201 in Melanoma Patients and Healthy Donors
| Subject | Frequency of CTLp to Flu matrix58–66 peptide |
|---|---|
| Patient 3 | 1/4,195 |
| Patient 4 | 1/7,426 |
| Patient 5 | 1/6,967 |
| Patient 7 | 1/5,471 |
| Patient 8 | 1/4,435 |
| Healthy donor 1 | 1/10,506 |
| Healthy donor 2 | 1/5,591 |
| Healthy donor 3 | 1/13,177 |
| Healthy donor 4 | 1/15,246 |
| Healthy donor 5 | 1/7,588 |
| Healthy donor 6 | 1/13,440 |
CTLp frequency was evaluated in peripheral blood by LDA as described in Materials and Methods using peptide-loaded T2 cells as APCs. Results are expressed as peptide-specific CTLp/PBLs.